DOWNLOAD LIBRARY

Date Document Type

View Presentation

View Presentation

Amended and Restated Bylaws

2015 Annual Report

2015 Letter to Shareholders

View Presentation

RG-101 in Combination with 4 Weeks of Oral Direct Acting
Antiviral Therapy Achieves High Virologic Response Rates in Treatment Naïve Genotype 1 and 4 Chronic Hepatitis C Patients: Interim Results from a Randomised, Multi-Center, Phase 2 Study

A single dose with anti-miR122 oligonucleotide RG-101 results in a less activated phenotype of NK cells in patients with chronic hepatitis C

RG-101 DEMONSTRATES FAVORABLE IN VITRO ANTIVIRAL ACTIVITY AND CROSS RESISTANCE PROFILE TO SUPPORT CLINICAL COMBINATION STUDIES IN HCV PATIENTS

Sequence Analysis for Resistance Monitoring Following a Single Dose of RG-101, an anti-miR Targeting microRNA-122, in Chronic Hepatitis C Patients